Assenagon Asset Management S.A. Arbutus Biopharma Corp Transaction History

Assenagon Asset Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 12, 2023	SELL	$1.91 - $2.85 $2.06 Million - $3.07 Million	-1,077,587 Reduced 56.86%	817,574 $1.91 Million
Q3 2022 Oct 27, 2022	SELL	$1.88 - $2.88 $425,340 - $651,585	-226,245 Reduced 10.66%	1,895,161 $3.62 Million
Q1 2022 Apr 25, 2022	BUY	$2.42 - $3.98 $4.92 Million - $8.1 Million	2,034,737 Added 2347.71%	2,121,406 $6.32 Million
Q4 2021 Feb 01, 2022	BUY	$3.11 - $4.61 $269,540 - $399,544	86,669 New	86,669 $337,000
Q3 2021 Oct 19, 2021	SELL	$2.65 - $4.62 $47,305 - $82,471	-17,851 Closed	0 $0
Q2 2021 Jul 15, 2021	BUY	$2.5 - $3.51 $44,627 - $62,657	17,851 New	17,851 $54,000
Q4 2020 Feb 01, 2021	SELL	$2.76 - $4.97 $122,439 - $220,479	-44,362 Closed	0 $0
Q3 2020 Oct 07, 2020	BUY	$1.75 - $6.2 $77,633 - $275,044	44,362 New	44,362 $139,000
Q3 2019 Oct 16, 2019	SELL	$1.34 - $2.4 $160,532 - $287,520	-119,800 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$1.46 - $4.44 $174,908 - $531,912	119,800 New	119,800 $249,000

155

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.